Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation.
Khaitov M RAleksandra NikonovaIlya KofiadiIgor ShilovskiyValeriy SmirnovOlga ElisytinaArtem MaerleArtem ShatilovAnastasia ShatilovaSergey AndreevIlya SergeevDmitry TrofimovTatyana LatyshevaNatalia IlynaAlexander MartynovSevastyan RabdanoEllina RuzanovaNikita S SavelievIuliia PletiukhinaAriana SafiVyacheslav RatnikovViktor GorelovViktor KaschenkoNatalya KucherenkoIrina UmarovaSvetlana MoskalevaSergei FabrichnikovOleg ZuevNikolai PavlovDaria KruchkoIgor BerzinDmitriy GoryachevVadim MerkulovGerman ShipulinSergey UdinVictor TrukhinRudolph ValentaVeronica SkvortsovaPublished in: Allergy (2023)
siR-7-EM/KK-46, a SARS-CoV-2-specific siRNA-peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID-19 compared to standard therapy in a randomized controlled trial.